Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Wave Life Sci Ord Sh
(NQ:
WVE
)
15.31
+0.70 (+4.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Wave Life Sci Ord Sh
< Previous
1
2
Next >
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
December 06, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
December 06, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
November 22, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023
November 03, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
September 28, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
September 25, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
September 05, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
August 03, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023
July 27, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes
June 26, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
May 23, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting
May 16, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
May 03, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023
April 26, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
April 20, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
March 29, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 22, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
March 02, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference
February 09, 2023
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
December 19, 2022
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
December 13, 2022
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference
November 09, 2022
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022
November 03, 2022
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses
October 03, 2022
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event
September 28, 2022
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022
July 28, 2022
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.